(Q34773159)

4 August 2017

Rapamycin treatment for a child with germline PTEN mutation (English)

1 reference

4 August 2017

1 reference

Toby N Trahair

2

0 references

Edwin P. Kirk

object named as

Edwin P Kirk

6

0 references

Robert C Baxter

object named as

Robert C Baxter

7

0 references

author name string

Deborah J Marsh

1

1 reference

4 August 2017

Janet L Martin

3

1 reference

4 August 2017

Wey Yeeng Chee

4

1 reference

4 August 2017

Jan Walker

5

1 reference

4 August 2017

Glenn M Marshall

8

1 reference

4 August 2017

22 April 2008

1 reference

Nature Clinical Practice Oncology

4 August 2017

1 reference

4 August 2017

5

1 reference

4 August 2017

6

1 reference

4 August 2017

357-361

1 reference

Proteus syndrome: diagnostic criteria, differential diagnosis, and patient evaluation

4 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1112

7 January 2021

Association of germline mutation in the PTEN tumour suppressor gene and Proteus and Proteus-like syndromes

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1112

7 January 2021

Germline mutation of the tumour suppressor PTEN in Proteus syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1112

7 January 2021

mTOR, translational control and human disease.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1112

7 January 2021

Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1112

7 January 2021

Cancer phenomics: RET and PTEN as illustrative models

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1112

7 January 2021

Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1112

7 January 2021

LKB1-dependent signaling pathways

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1112

7 January 2021

Rapamycin causes regression of astrocytomas in tuberous sclerosis complex

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1112

7 January 2021

Current development of mTOR inhibitors as anticancer agents

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1112

7 January 2021

Upstream signaling inhibition enhances rapamycin effect on growth of kidney cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1112

7 January 2021

Combining an mTOR antagonist and receptor tyrosine kinase inhibitors for the treatment of prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1112

7 January 2021

Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1112

7 January 2021

Cancer drugs to treat birth defects

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1112

7 January 2021

Hemangiomas in children

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1112

7 January 2021

Cellular actions of the insulin-like growth factor binding proteins

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1112

7 January 2021

Elevated serum insulin-like growth factor binding protein-2 as a prognostic marker in patients with ovarian cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1112

7 January 2021

Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1112

7 January 2021

PTEN-induction in U251 glioma cells decreases the expression of insulin-like growth factor binding protein-2.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1112

7 January 2021

Expression of insulin-like growth factor binding protein-2 by MCF-7 breast cancer cells is regulated through the phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1112

7 January 2021

Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1112

7 January 2021

The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1112

7 January 2021

Identifiers

DOI

10.1038/NCPONC1112

1 reference

4 August 2017

1 reference